U
CATX icon

UBS’s Perspective Therapeutics CATX Stock Holding History

UBS’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$10K Buy
605
+105
+21% +$2.6K ﹤0.01% 8816
2014
Q2 		$16K Sell
500
-1,656
-77% -$41.5K ﹤0.01% 8336
2014
Q1 		$47K Buy
+2,156
New +$21.9K ﹤0.01% 6916
2013
Q4 		– Sell
-203
Closed -$1K – 10414
2013
Q3 		$1K Buy
203
+21
+12% +$131 ﹤0.01% 10127
2013
Q2 		$1K Buy
+182
New +$981 ﹤0.01% 9999

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's CATX Position: Q3 2014 in Review

UBS increased its Perspective Therapeutics (CATX) stake by 21% in Q3 2014, buying an estimated $2.6K and bringing the position to 605 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #8816.

UBS first reported a position in CATX in Q2 2013 and has held it in 5 quarters since. The position peaked at $47K in Q1 2014. 27 funds tracked by Wall St. Rank hold CATX as of Q3 2014.

  • UBS held 605 shares of Perspective Therapeutics worth $10K as of Q3 2014.
  • UBS bought 105 Perspective Therapeutics shares in Q3 2014, an estimated $2.6K.
  • Perspective Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8816 holding.
  • UBS first reported a position in Perspective Therapeutics in Q2 2013 and has held it in 5 quarters since.
  • UBS's Perspective Therapeutics position peaked at $47K in Q1 2014.
  • 27 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.